CryoCell International Inc (CCEL)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • AMEX
Market Cap: $39.10M
Last updated: Nov 17, 2026 at 11:04 AM ET
CryoCell International Inc (CCEL) Financials: Revenue, Profit and Cash Flow
CryoCell International reported revenue of $31.57M for the fiscal year ended Nov 30, 2025, down 1.3% from the year before. That year, net income was -$2.43M with a net margin of -7.7%, operating cash flow was $5.48M and free cash flow was $5.25M. The quarter ended Aug 31, 2026 had revenue of $7.82M and net income of $1.27M.
Revenue and Margins
The operating margin was 1.5% in the fiscal year ended Nov 2025. Over the 9 years to Nov 2025, revenue grew from $23.13M, a compound annual rate of 3.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Nov 2025 | $31.57M | -1.3% | 76.6% | 1.5% | -7.7% |
| Nov 2024 | $31.99M | +2.0% | 75.2% | 10.9% | 1.3% |
| Nov 2023 | $31.34M | +3.3% | 73.2% | -39.3% | -30.4% |
| Nov 2022 | $30.34M | +5.0% | 71.0% | 13.3% | 9.1% |
| Nov 2021 | $28.88M | -7.3% | 68.9% | 13.9% | 7.2% |
| Nov 2020 | $31.15M | -2.1% | 69.0% | 24.6% | 11.6% |
| Nov 2019 | $31.82M | +8.9% | 68.5% | 15.9% | 7.2% |
| Nov 2018 | $29.22M | +10.7% | 70.8% | 17.8% | -2.9% |
| Nov 2017 | $26.39M | +14.1% | 74.5% | 19.0% | 8.8% |
| Nov 2016 | $23.13M | N/A | 75.0% | 1.9% | -5.7% |
Income Statement
In the fiscal year ended Nov 2025, the company posted a net loss after a profit the year before. In the quarter ended Aug 2026, net income rose 69.5% from the same quarter a year earlier.
Annual
| Line item | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 | Nov 2020 | Nov 2019 | Nov 2018 | Nov 2017 | Nov 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.57M | $31.99M | $31.34M | $30.34M | $28.88M | $31.15M | $31.82M | $29.22M | $26.39M | $23.13M |
| Cost of revenue | $7.38M | $7.95M | $8.39M | $8.79M | $8.99M | $9.66M | $10.04M | $8.54M | $6.72M | $5.77M |
| Gross profit | $24.19M | $24.04M | $22.95M | $21.54M | $19.90M | $21.49M | $21.78M | $20.68M | $19.66M | $17.35M |
| Research and development | $376.26K | $1.24M | $1.17M | $384.79K | $49.87K | $23.85K | $30.14K | $91.84K | $41.16K | $53.10K |
| Operating income | $482.39K | $3.48M | -$12.30M | $4.02M | $4.02M | $7.66M | $5.06M | $5.19M | $5.01M | $433.59K |
| Net income | -$2.43M | $402.10K | -$9.52M | $2.77M | $2.08M | $3.62M | $2.29M | -$854.82K | $2.32M | -$1.32M |
| EBITDA | $1.12M | $5.71M | -$10.40M | $6.67M | $5.39M | N/A | $5.61M | $5.59M | $5.28M | N/A |
Quarterly
| Line item | Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.82M | $7.78M | $7.68M | $7.84M | $7.83M | $7.93M | $7.97M | $8.02M | $8.07M | $8.04M | $7.85M | $7.88M |
| Gross profit | $6.21M | $6.10M | $6.03M | $6.11M | $6.02M | $6.07M | $5.98M | $6.29M | $5.94M | $6.02M | $5.79M | $5.85M |
| Operating income | $2.19M | $1.20M | $765.13K | -$3.97M | $1.90M | $1.49M | $1.06M | -$122.35K | $1.39M | $1.39M | $821.22K | -$16.18M |
| Net income | $1.27M | $554.59K | $47.11K | -$3.82M | $749.41K | $355.79K | $282.86K | -$1.86M | $1.05M | $655.79K | $556.24K | -$11.19M |
Balance Sheet
As of Nov 2025, total debt of $11.53M exceeded cash and equivalents by $11.21M. Shareholder equity was negative, at -$18.61M, as total liabilities of $80.33M exceeded total assets of $61.73M.
Annual
| Line item | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 | Nov 2020 | Nov 2019 | Nov 2018 | Nov 2017 | Nov 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $61.73M | $64.68M | $61.22M | $64.89M | $60.66M | $46.20M | $42.89M | $42.39M | $23.91M | $19.54M |
| Current assets | $11.76M | $12.55M | $9.45M | $9.61M | $15.78M | $18.56M | $15.39M | $14.76M | $12.74M | $9.01M |
| Cash and equivalents | $319.03K | $560.96K | $406.07K | $1.70M | $8.26M | $10.36M | $6.54M | $6.04M | $6.28M | $3.50M |
| Total liabilities | $80.33M | $77.89M | $72.25M | $66.41M | $56.48M | $48.87M | $49.84M | $51.30M | $36.41M | $34.95M |
| Short-term debt | $2.48M | $3.69M | $1.39M | $2.42M | $1.90M | $3.10M | $3.10M | $3.10M | $2.00M | $2.00M |
| Long-term debt | $9.05M | $9.19M | $9.31M | $9.45M | $875.00K | $3.72M | $7.28M | $11.27M | $6.72M | $9.24M |
| Shareholder equity | -$18.61M | -$13.22M | -$11.03M | -$1.52M | $4.18M | -$2.67M | -$6.95M | -$8.91M | -$12.50M | -$15.41M |
Quarterly
| Line item | Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $62.30M | $60.71M | $60.88M | $61.73M | $63.17M | $64.44M | $64.38M | $64.68M | $62.93M | $62.57M | $61.71M | $61.22M |
| Total liabilities | $78.70M | $78.46M | $79.29M | $80.33M | $78.00M | $80.00M | $79.04M | $77.89M | $72.49M | $73.31M | $72.05M | $72.25M |
| Cash and equivalents | $1.43M | $507.30K | $249.67K | $319.03K | $265.21K | $137.49K | $223.12K | $560.96K | $197.44K | $469.19K | $247.11K | $406.07K |
| Shareholder equity | -$16.39M | -$17.76M | -$18.40M | -$18.61M | -$14.83M | -$15.56M | -$14.66M | -$13.22M | -$9.56M | -$10.74M | -$10.34M | -$11.03M |
Cash Flow
In the fiscal year ended Nov 2025, free cash flow was 95.8% of operating cash flow. Dividends and share repurchases together came to 64.8% of it.
Annual
| Line item | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 | Nov 2020 | Nov 2019 | Nov 2018 | Nov 2017 | Nov 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.48M | $6.01M | $8.92M | $8.57M | $7.93M | $8.47M | $6.29M | $5.33M | $5.72M | $4.99M |
| Capital expenditures | $230.47K | $2.40M | $6.84M | $12.17M | $1.83M | $99.96K | $662.29K | $446.16K | $98.33K | $342.98K |
| Free cash flow | $5.25M | $3.61M | $2.08M | -$3.60M | $6.09M | $8.37M | $5.63M | $4.89M | $5.62M | $4.64M |
| Dividends paid | $3.23M | $2.02M | $0 | $7.67M | $0 | N/A | N/A | $0 | $0 | $0 |
| Share repurchases | $169.50K | $1.42M | $799.04K | $1.82M | $249.38K | $0 | $992.24K | N/A | $446.62K | $10.81M |
| Investing cash flow | -$975.33K | -$4.88M | -$8.14M | -$15.28M | -$6.95M | $357.49K | -$662.29K | -$11.28M | $93.03K | -$369.73K |
| Financing cash flow | -$4.75M | -$979.12K | -$2.07M | $147.86K | -$3.07M | -$5.00M | -$5.13M | $5.71M | -$3.03M | -$5.27M |
Quarterly
| Line item | Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.14M | $1.85M | $651.83K | $1.28M | $2.54M | $707.01K | $954.06K | $2.16M | $2.44M | $1.77M | -$356.87K | $3.34M |
| Capital expenditures | $101.88K | $32.70K | $67.06K | $67.23K | $38.79K | $62.41K | $62.05K | $8.35K | $185.71K | $1.75M | $457.72K | $1.71M |
| Free cash flow | $1.04M | $1.81M | $584.76K | $1.21M | $2.50M | $644.61K | $892.01K | $2.15M | $2.25M | $21.55K | -$814.59K | $1.63M |
Frequently Asked Questions About CCEL
What is CryoCell International's annual revenue?
CryoCell International reported revenue of $31.57M for the fiscal year ended Nov 30, 2025.
How fast is CryoCell International's revenue growing?
Revenue was down 1.3% for the fiscal year ended Nov 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 1.3%.
Is CryoCell International profitable?
No. CryoCell International reported net income of -$2.43M for the fiscal year ended Nov 30, 2025, with a net margin of -7.7%.
How much free cash flow does CCEL generate?
For the fiscal year ended Nov 30, 2025, operating cash flow of $5.48M minus capital expenditures of $230.47K produced free cash flow of $5.25M.
How much debt does CryoCell International have?
The balance sheet dated Nov 30, 2025 reported long-term debt of $9.05M, short-term debt of $2.48M and cash and equivalents of $319.03K.
CCEL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors